Trial Profile

A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Dec 2023 According to a Henlius Biopharmaceuticals media release, results from this study were presented at the European Society for Medical Oncology Asia (ESMO Asia) Congress 2023.
05 Dec 2023 Results ( N=31, Cut of 2 July 2023) presented in a Henlius Biopharmaceuticals media release.
09 Jun 2022 Planned initiation date changed from 19 May 2022 to 19 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com